Mouse IP injection GII.11
Mouse IP injection GII.11 CV-1A5 scFv Human (phage display selection) GI.4 VLP (baculo) GI.1*, GI.2*, GI.3*, GI.4 B , GI.6*, GII.1, GII.3, GII.4 (r104* nb ), GII.5*, GII.6*, GII.7*, GII.12, GII.13 --- [245] HJT-R3-A9^ scFv Human (phage display selection) GII.4 (HOV) VLP GI.1, GI.2, GI.4, GI.5*, GI.6*, GI.7*, GI.8, GI.9, GII. SUPPLEMENTARY TABLE FOOTNOTES   Tables S1-4 Monoclonal antibodies (mAbs) within the tables are time-ordered and list the earliest characterized mAb of each subset first and the most recently generated mAb last. mAbs marked with (^) have reported variable recognition activity to certain genotypes of norovirus due to binding a masked or conformationally-hidden epitope. The reactive genotypes were updated to reflect current genotyping criteria by cross-checking provided sequences with the RIVM online genotyping tool https://www.rivm.nl/mpf/typingtool/norovirus. Genotypes and strains marked with an asterisk (*) were reported to react weakly with the mAb. Superscript "B" denotes reported HBGA blockade activity, superscript "H" denotes reported hemagglutination inhibition activity (HAI), superscript "N" denotes reported neutralization activity either in vitro or in vivo, and superscripts "nb" and "nn" indicate the mAbs failed to block or neutralize, respectively. Amino acids that are underlined indicate residues that were determined to be essential for mAb binding. References for each mAb include reports of isolation, characterization, and representative applications. Table S5 VLP immunization or viral infection was followed by T cell isolation and stimulation with overlapping peptides spanning a norovirus genotype of interest. Changes in cytokine release are recorded here as well as their T cell restriction (CD4+ or CD8+). Minimal binding regions and anchor residues are underlined. Weak reactivity is denoted with an asterisk by the genotype and strain tested. Though many of these sequences have been reported to be highly conserved across norovirus genotypes, only three have been verified to induce cross-genotypic T cell responses in vitro (bolded epitopes).
